Nuvation Bio Inc. (NUVB) Stock

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, is dedicated to developing innovative therapeutic candidates for oncology. The company's lead product candidate, NUV-422, is a small molecule inhibitor targeting cyclin-dependent kinases (CDK)2, CDK4, and CDK6, which are critical in regulating the cell cycle and are implicated in various cancers.

Additionally, Nuvation Bio is developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins controlling tumor growth and differentiation. Another promising candidate is NUV-569, a differentiated oral small molecule selective inhibitor of the Wee1 kinase, which plays a crucial role in DNA damage repair.

The company's pipeline also includes NUV-1182, an adenosine receptor inhibitor, and a drug-drug conjugate (DDC) platform. This DDC platform focuses on targeting poly ADP ribose polymerase (PARP) inhibitors to anti-cancer warheads of existing drugs, aiming to address ER+ breast and ovarian cancer.

Nuvation Bio Inc. was formerly known as RePharmation Inc. and underwent a name change in April 2019. Founded in 2018, the company is headquartered in New York, New York, and continues to advance its portfolio of oncology treatments through cutting-edge research and development.